The Source for Neurovascular News and Education

March 29, 2024


In a case series, researchers highlight the importance of careful consideration of EVD placement and use of a platelet-function-based therapy regimen.

 

Stent-assisted coiling in patients with ruptured aneurysms can be performed with good technical success, according to a case series reported in the Journal of NeuroInterventional Surgery. The researchers say their strict protocol helped them achieve immediate total or near-total aneurysm occlusion in up to 97% of patients treated with a combination of stents and coils.

“In our experience, stent techniques have provided a high rate of technical success without intra- or periprocedural hemorrhage, and with good late neurological outcomes,” write Jose E. Cohen, MD (Hadassah-Hebrew University Medical Center, Jerusalem), and colleagues.

They employed a protocol for stent-based treatment based on a low threshold for external ventricular drain (EVD) placement before stenting, and preprocedure administration of aspirin and clopidogrel with platelet testing to “ensure that response falls within a safe range to limit the risk of both hemorrhage and stent-related thrombus formation.”

Cohen and colleagues conducted a retrospective review of clinical records from 47 patients with acutely ruptured aneurysms treated at their institution with stent techniques during the early acute phase of aneurysmal rupture between June 2011 and June 2016. Of the included patients, 46 had subarachnoid hemorrhage; patients harbored 71 aneurysms, including 56 in the acute phase.

Single-stent techniques were used in the majority of the 56 acute stage aneurysms (n = 39) with dual-stent techniques used in the remainder. Per protocol, EVDs were placed before embolization in 92% of patients.

Only four patients experienced intraprocedure thromboembolic complications due to hyporesponse to antiplatelet therapy. These patients were all treated with stent-assisted coiling and the complications were successfully managed with intra-arterial antiplatelet agents.

The majority of patients (96%) survived the procedures. Among survivors, there was complete aneurysm occlusion at 9- to 12-month follow-up in 90% of patients treated with stent-assisted coiling, in 66% of aneurysms treated with flow-diverter-assisted coiling, and in 86% of aneurysms treated with flow diverter alone.

 

Reassuring Study

In their discussion of the results, Cohen and colleagues credit the low rate of hemorrhagic complications to the use of flow diverter stents and routine EVD placement prior to embolization in patients with actual or anticipated hydrocephalus.

“In this way, we avoided placing ventriculostomy under double antiplatelet therapy and further reduced the overall risk of hemorrhage,” they write.

In fact, emphasis on the need for careful consideration of EVD placement is among the best feature of the study, commented David F. Kallmes, MD (Mayo Clinic, Rochester, MN). To Neurovascular Exchange, he said the results of this study are incremental and reinforce what has already been published on the topic.

“This study offers more comfort to practitioners that, if needed, stent or flow diverter should be considered,” he said.

However, Kallmes did point out one issue that was not addressed with the case series: the fact that there may be future advances to technology that will facilitate stent and flow-diverter usage in ruptured cases. Specifically, new coatings, materials, or designs could diminish or eradicate risk of thromboembolism, Kallmes said, citing Shield Technology (Medtronic) as one example of ongoing efforts aimed at reducing thrombogenicity.

“There is animal data showing benefit in reducing neointima and some suggestion that thromboembolism is diminished, but this is very early and how clinical trials will be done to prove efficacy remains problematic,” Kallmes said. “That is, who will want to randomize patients to no antiplatelet therapy to show benefit of coatings?”

 


Sources:

Cohen JE, Gomori JM, Leker RR, et al. Stent and flow diverter assisted treatment of acutely ruptured brain aneurysms. J NeuroIntervent Surg. 2018;Epub ahead of print.

 

Disclosures:

  • Cohen reported no competing interests.
  • Kallmes reports receiving research funding from and being a consultant for Medtronic.  

 

 

Monday, October 26 2020

Stroke rates for the balloon-expandable device far exceeded those of the Evolut R; conscious...

Read More »

Monday, October 26 2020

Safety goals were met in the trial, but better efficacy may require ensuring complete coverage of...

Read More »

Wednesday, September 23 2020

The findings “reinforce that this is absolutely the right thing to do and that we need to set up...

Read More »

Tuesday, July 21 2020

Whether COVID-19 adds risk by virtue of being a comorbidity or due to direct effects is unknown. A...

Read More »

Friday, May 8 2020

In some cases, large strokes are the first presentation of COVID-19 in younger patients, but...

Read More »

Monday, April 6 2020

Clopidogrel added to rivaroxaban and aspirin increased bleeding with no added protection from limb or...

Read More »

Monday, April 6 2020

Although rivaroxaban patients had more bleeding, the events were not severe and none were...

Read More »

Monday, April 6 2020

The strokes do not appear related to valve thrombosis or structural degeneration, but rather to...

Read More »

Thursday, January 23 2020

A fundamental unanswered question is whether any type of oral anticoagulation is needed in the...

Read More »

Monday, January 6 2020

Though periprocedural results look good, there are some questions about its rapid rise when...

Read More »

Wednesday, August 21 2019

In addition, an infarct in a new territory did not emerge as an independent predictor of...

Read More »

Wednesday, August 21 2019

The procedure—a hybrid of surgical and endovascular techniques—offers low stroke rates and a short...

Read More »